Search Results - "METRO, Giulio"

Refine Results
  1. 1

    Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis by Addeo, Alfredo, Banna, Giuseppe Luigi, Metro, Giulio, Di Maio, Massimo

    Published in Frontiers in oncology (16-04-2019)
    “…Checkpoint inhibitors plus platinum-based chemotherapy have shown superiority compared to chemotherapy alone as first-line therapy in advanced non-small cell…”
    Get full text
    Journal Article
  2. 2

    Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports by Inno, Alessandro, Maurea, Nicola, Metro, Giulio, Carbone, Andreina, Russo, Antonio, Gori, Stefania

    Published in Cancer Immunology, Immunotherapy (01-10-2021)
    “…Treatment with immune checkpoint inhibitors (ICIs) can be complicated by cardiovascular toxicity, including pericardial disease. To date, no prospective…”
    Get full text
    Journal Article
  3. 3

    Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies by Koulouris, Andreas, Tsagkaris, Christos, Corriero, Anna Chiara, Metro, Giulio, Mountzios, Giannis

    Published in Cancers (08-07-2022)
    “…Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) in advanced mutant Non-Small Cell Lung Cancer (NSCLC)…”
    Get full text
    Journal Article
  4. 4

    Therapeutic options targeting angiogenesis in nonsmall cell lung cancer by Crinò, Lucio, Metro, Giulio

    Published in European respiratory review (01-03-2014)
    “…There is a major unmet medical need for effective and well-tolerated treatment options for patients with advanced nonsmall cell lung cancer (NSCLC), in both…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence by Ricciuti, Biagio, Brambilla, Marta, Metro, Giulio, Baglivo, Sara, Matocci, Roberta, Pirro, Matteo, Chiari, Rita

    “…In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK…”
    Get full text
    Journal Article
  7. 7

    The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks by De Giglio, Andrea, Ricciuti, Biagio, Metro, Giulio

    Published in Drugs in Context (02-05-2023)
    “…This Editorial by De Giglio, Ricciuti and Metro introduces the series :…”
    Get full text
    Journal Article
  8. 8

    Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy by Cortellini, Alessio, Di Maio, Massimo, Nigro, Olga, Leonetti, Alessandro, Cortinovis, Diego L, Aerts, Joachim GJV, Guaitoli, Giorgia, Barbieri, Fausto, Giusti, Raffaele, Ferrara, Miriam G, Bria, Emilio, D'Argento, Ettore, Grossi, Francesco, Rijavec, Erika, Guida, Annalisa, Berardi, Rossana, Torniai, Mariangela, Sforza, Vincenzo, Genova, Carlo, Mazzoni, Francesca, Garassino, Marina Chiara, De Toma, Alessandro, Signorelli, Diego, Gelibter, Alain, Siringo, Marco, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Della Gravara, Luigi, Inno, Alessandro, Michele, De Tursi, Grassadonia, Antonino, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Filetti, Marco, Santini, Daniele, Citarella, Fabrizio, Russano, Marco, Cantini, Luca, Tuzi, Alessandro, Bordi, Paola, Minuti, Gabriele, Landi, Lorenza, Ricciardi, Serena, Migliorino, Maria R, Passiglia, Francesco, Bironzo, Paolo, Metro, Giulio, Adamo, Vincenzo, Russo, Alessandro, Spinelli, Gian Paolo, Banna, Giuseppe L, Friedlaender, Alex, Addeo, Alfredo, Cannita, Katia, Ficorella, Corrado, Porzio, Giampiero, Pinato, David J

    Published in Journal for immunotherapy of cancer (01-04-2021)
    “…BackgroundSome concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors…”
    Get full text
    Journal Article
  9. 9

    A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives by Bertolaccini, Luca, De Giglio, Andrea, Gariazzo, Eleonora, Metro, Giulio

    Published in Oncology and therapy (01-06-2024)
    “…Management of stage II–III non-small cell lung cancer (NSCLC) has been dramatically revolutionized by studies testing the addition of immunotherapy (IO) to…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer by Giunta, Emilio Francesco, Signori, Alessio, West, Howard Jack, Metro, Giulio, Friedlaender, Alex, Parikh, Kaushal, Banna, Giuseppe Luigi, Addeo, Alfredo

    Published in Frontiers in oncology (14-06-2022)
    “…Background Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease by Marinelli, Daniele, Siringo, Marco, Metro, Giulio, Ricciuti, Biagio, Gelibter, Alain J

    Published in Drugs in Context (12-10-2022)
    “…Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK , ROS1 and NTRK rearrangements are found in…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Non-small-cell lung cancer: how to manage RET-positive disease by Andrini, Elisa, Mosca, Mirta, Galvani, Linda, Sperandi, Francesca, Ricciuti, Biagio, Metro, Giulio, Lamberti, Giuseppe

    Published in Drugs in Context (11-07-2022)
    “…Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy by Ricciuti, Biagio, Baglivo, Sara, Paglialunga, Luca, De Giglio, Andrea, Bellezza, Guido, Chiari, Rita, Crinò, Lucio, Metro, Giulio

    Published in Therapeutic Advances in Medical Oncology (01-06-2017)
    “…The identification of epidermal growth factor receptor (EGFR) mutations represented a fundamental step forward in the treatment of advanced non-small cell lung…”
    Get full text
    Book Review Journal Article
  19. 19

    RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature by Baglivo, Sara, Ludovini, Vienna, Moretti, Riccardo, Bellezza, Guido, Sidoni, Angelo, Roila, Fausto, Metro, Giulio

    Published in Oncology and therapy (01-12-2020)
    “…Patients with epidermal growth factor receptor and anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC) generally respond poorly to treatment…”
    Get full text
    Journal Article
  20. 20